Abstract
Lung cancer (LC) is one of the leading cause of cancer related morbidity and mortality. Despite advances in first and second line (2L) therapy, limited evidence is available about effective treatment possibilities in third (3L) and further lines (4+L) in metastatic LC. Our objective was to investigate real life outcome in patients receiving therapy beyond 2L for LC.
All prevalent LC patients presented at the tumor board between December 2018 and May 2019 (N=399) were reviewed. Systemic treatment for 3L was recommended in 32 cases (8%). Patient demographics, cancer type, response to previous therapies and survival until January 2020 were analyzed.
Mean age of patients at initiation of 3L therapy was 66 ± 8 years, male to female ratio 14:18. Patient’s performance status was good (0-1), 87% had a history of smoking and 31% concomitant lung disease. Majority had adenocarcinoma (84%), while 16% were diagnosed with other types of LC. Interval between IL and 3L therapy was 24.6 months [range:7.0-95.0]. Single agent chemotherapy was administered in 41%, docetaxel-nintedanib in 34%, while immunotherapy in 25%. Forty-four % of patients had ongoing treatment on 3L or stable disease after chemotherapy, in 31% 4+L was started, 16% were lost to follow-up or died, 9% discontinued due to progression but were not fit enough for further therapy. Duration of response was at least 6 months in the majority of patients (81%) mainly using immunotherapy or docetaxel-nintedanib.
Our study confirmed that 8% of metastatic LC patients are eligible for treatment beyond 2L, however choice of treatment and outcome are based on very low evidence data. Higher number of real life results are needed close this gap.
Footnotes
Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1691.
This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2020